A Q&A guide to the commercialisation of healthcare in the UK.

This Q&A provides an overview of the regulatory framework for the commercialisation of medical products in the UK. It covers the key requirements for manufacturing, advertising and selling drugs, medical devices, biological products and natural health products.

This resource may be affected by Brexit. Please note the law-stated date of the resource, and that it may not incorporate all recent developments. The UK left the EU on 31 January 2020. The transition period ended on 31 December 2020 (see Brexit essentials: Q&As on agreements and operation of UK law: What happened at the end of the transition period?). This Country Q&A will be updated in line with our usual publication schedule following the end of transition (see Guide to assessing legal change after end of post-Brexit transition period and UK law after end of post-Brexit transition period: overview). If you require more specific information, please see Beyond Brexit: the legal implications.